Sionna Therapeutics, Inc. (SION)
| Market Cap | 1.51B +154.2% |
| Revenue (ttm) | n/a |
| Net Income | -85.57M |
| EPS | -1.92 |
| Shares Out | 45.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,758 |
| Open | 35.29 |
| Previous Close | 35.37 |
| Day's Range | 32.26 - 35.44 |
| 52-Week Range | 13.51 - 48.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.60 (+53.98%) |
| Earnings Date | May 12, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SION stock is "Buy." The 12-month stock price target is $51.6, which is an increase of 53.98% from the latest price.
News
Sionna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
A novel approach targeting the NBD1 domain in cystic fibrosis aims to address unmet needs for the majority of patients not reaching normal CFTR function. Two lead compounds, SION-719 and SION-451, are advancing in parallel with pivotal data expected in summer 2026.
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c...
Sionna Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Two clinical-stage NBD1 stabilizers are advancing in cystic fibrosis, with key phase II and healthy volunteer data expected this summer. The company prioritizes a novel dual combination targeting broad patient needs, aiming for superior efficacy and validated by robust assay science.
Sionna Therapeutics downgraded at Freedom Broker with unchanged target
As previously reported, Freedom Broker analyst Ilya Zubkov downgraded Sionna Therapeutics (SION) to Hold from Buy with an unchanged price target of $38. Sionna’s Q1 update confirms that clinical execu...
Sionna Therapeutics downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded Sionna Therapeutics (SION) to Hold from Buy.
Sionna Therapeutics price target raised to $55 from $44 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Sionna Therapeutics (SION) to $55 from $44 and keeps a Buy rating on the shares. After a deep dive Into…
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c...
Sionna Therapeutics reports Q1 EPS (60c), consensus (50c)
“We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna,” s...
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on trac...
Sionna Therapeutics Earnings release: Q1 2026
Sionna Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Sionna Therapeutics Quarterly report: Q1 2026
Sionna Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Sionna Therapeutics Slides: Corporate presentation
Sionna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Sionna Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $53 price target The company’s focus remains on developing next-generation CFTR modulators th...
Sionna Therapeutics price target raised to $63 from $52 at JonesResearch
JonesResearch raised the firm’s price target on Sionna Therapeutics (SION) to $63 from $52 and keeps a Buy rating on the shares after the company completed enrollment in the Phase…
Sionna Therapeutics Proxy statement: Proxy filing
Sionna Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Sionna Therapeutics Proxy statement: Proxy filing
Sionna Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Sionna Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing two NBD1 stabilizers for cystic fibrosis, targeting significant unmet need with both add-on and dual combination strategies. Key clinical data from ongoing studies are expected by mid-2026, supported by strong financial resources and a validated predictive assay.
Sionna Therapeutics price target raised to $50 from $45 at Guggenheim
Guggenheim raised the firm’s price target on Sionna Therapeutics (SION) to $50 from $45 and keeps a Buy rating on the shares after the company announced FY25 earnings. The firm…
Sionna Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted the strategy to address unmet needs in CF by developing NBD1 stabilizers, with a focus on dual combinations aiming for clinically meaningful improvements in CFTR function. The phase II study is designed for robust mechanistic proof, and future plans include dose-ranging and co-formulation.
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics files automatic mixed securities shelf
08:21 EST Sionna Therapeutics (SION) files automatic mixed securities shelf
Sionna Therapeutics reports Q4 EPS (46c), consensus (55c)
Cash, cash equivalents and marketable securities totaled$310.3 millionas of December 31, 2025. Sionna expects its current cash position to fund operations into 2028. “2025 was a remarkable and transfo...